Device Trial Radar · NCT04002479
Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
37
Planned (sponsor's estimate)
Start
Mar 31, 2023
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Alpha Tau Medical LTD.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jun 28, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for advanced pancreatic cancer.
Conditions
- Pancreatic Cancer
- Unresectable Pancreatic Cancer
- Metastatic Pancreatic Cancer
- Pancreatic Adenocarcinoma
Interventions
Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)Device
An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Feasibility - DaRT seed placementTime frame: Day 0 (Day of insertion)
- Safety - Adverse eventsTime frame: 3 months
- Safety - Adverse eventsTime frame: 3 to 24 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Centre Hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, Canada
Jewish General Hospital
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.